Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501327 · ClinicalTrials.gov registry record · Phase 2
Dose Regimen Study of SLI-F06 in Healthy Volunteers
A Phase 2 study of Scar and Wound Healing, sponsored by Scarless Laboratories.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05501327: Recruiting Phase 2 study of Scar and Wound Healing, sponsored by Scarless Laboratories.
NCT05501327 is a Phase 2 study of Scar and Wound Healing that is actively recruiting participants, run by Scarless Laboratories. The registered enrollment target is 30 participants, below the 47-participant average among 15 other Scar trials with a reported enrollment target (36% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501327, a Phase 2 study of Scar and Wound Healing, is actively recruiting participants, sponsored by Scarless Laboratories.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance
Primary Outcome
Exploratory scale for observer to assess different scar parameters, including Surface Area, Elevation / Depression, Relief, Thickness, Pliability, Vascularity and Pigmentation. The observer then makes an Overall global assessment (scale 0 to -3) of the scar based on the clinical assessment of the scar parameters. All parameters are assessed on a scale of 0-3 (except pigmentation, -3 \[hypo\] to +3 \[hyper\]), where 0 correlates to a scar that is indistinguishable from normal skin with greater de
Conditions Studied
Interventions
- DRUG SLI-F06
Study Locations (2)
California
- California Dermatology & Clinical Research Institute - Encinitas
Texas
- DermResearch - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
What NCT05501327 shows while recruiting
NCT05501327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 47-participant average among 15 other Scar trials with a reported enrollment target (36% lower).
The record links to 2 conditions, with Scar appearing as the primary indexed condition, and to 1 intervention - of which SLI-F06 is the first listed.
NCT05501327 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT05501327 about?
NCT05501327 is a clinical study titled "Dose Regimen Study of SLI-F06 in Healthy Volunteers". Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance
What is the current status of trial NCT05501327?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-07-25. Estimated completion is 2024-10-25.
What conditions does trial NCT05501327 study?
This clinical trial studies the following conditions: Scar, Wound Healing.
What interventions are being tested in trial NCT05501327?
The interventions under investigation include: SLI-F06 (DRUG).
Who is sponsoring clinical trial NCT05501327?
This trial is sponsored by Scarless Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05501327 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scar
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05501327's enrollment target sits among peer trials
30 8th of 15 higher than 5 of 15 other Scar trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scar trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery
COMPLETED · Phase 2
-
Microneedling vs Dermabrasion for Early Facial Scar Resurfacing
RECRUITING · NA
-
Zinc Oxide Versus Petrolatum Following Skin Surgery
RECRUITING · Early Phase 1
-
Paraffin Wax and Exercise Prospective
RECRUITING · NA
-
Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI